Literature DB >> 15286681

Oncolytic viral therapies.

Eugene Lin1, John Nemunaitis.   

Abstract

Molecular research has vastly advanced our understanding of the mechanism of cancer growth and spread. Targeted approaches utilizing molecular science have yielded provocative results in the treatment of cancer. Oncolytic viruses genetically programmed to replicate within cancer cells and directly induce toxic effect via cell lysis or apoptosis are currently being explored in the clinic. Safety has been confirmed and despite variable efficacy results several dramatic responses have been observed with some oncolytic viruses. This review summarizes results of clinical trials with oncolytic viruses in cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15286681     DOI: 10.1038/sj.cgt.7700733

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  44 in total

Review 1.  The good viruses: viral mutualistic symbioses.

Authors:  Marilyn J Roossinck
Journal:  Nat Rev Microbiol       Date:  2011-01-04       Impact factor: 60.633

Review 2.  Fighting cancer with oncolytic viruses.

Authors:  Yuti Chernajovsky; Lorna Layward; Nicholas Lemoine
Journal:  BMJ       Date:  2006-01-21

3.  Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.

Authors:  Tae-Jin Song; David P Eisenberg; Prasad S Adusumilli; Michael Hezel; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

4.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

Review 5.  Gene therapy in head and neck cancer: a review.

Authors:  E Chisholm; U Bapat; C Chisholm; G Alusi; G Vassaux
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

6.  E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Authors:  S C Cheong; Y Wang; J-H Meng; R Hill; K Sweeney; D Kirn; N R Lemoine; G Halldén
Journal:  Cancer Gene Ther       Date:  2007-11-23       Impact factor: 5.987

7.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 8.  Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option?

Authors:  Giorgia Pastorin
Journal:  Pharm Res       Date:  2009-01-14       Impact factor: 4.200

9.  Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Authors:  Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

Review 10.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.